LIfT BioSciences expands into Ireland for manufacturing & clinical operations
18. November 2024 02:00 ET
|
LIfT BioSciences
LIfT BioSciences expands into Ireland for manufacturing & clinical operations London, 18 November 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company preparing...
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
24. September 2024 02:00 ET
|
LIfT BioSciences
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS London, 24 September 2024–...
LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors
01. Juli 2024 02:00 ET
|
LIfT BioSciences
LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors London, 1 July 2024– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
24. Mai 2024 02:00 ET
|
LIfT BioSciences
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants
16. Mai 2024 02:00 ET
|
LIfT BioSciences
LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell...
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors
21. Dezember 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors London, 21 December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company...
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy
03. August 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy Positive data supports the potential of the iN-LIfT platform to...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
06. Juli 2023 07:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
06. Juli 2023 02:00 ET
|
LIfT BioSciences
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...
LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids
04. Mai 2023 07:00 ET
|
LIfT BioSciences
- IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model - IMAN is the world’s first neutrophil-based cell therapy, generated...